bih.button.backtotop.text
HomeLab Services GuideTests
BROWSE BY TEST NAME
#
%
1
2
3
5
8
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Z
Clear
Overview
ข้อมูลทั่วไป Specimen
ข้อมูลสิ่งส่งตรวจ Performance
ข้อมูลการทดสอบ Clinical & Interpretation
ข้อมูลทางคลินิก
 
Test Code (รหัสการทดสอบ):
092-10-0025
Order Name (ชื่อการทดสอบ):
APOE Genotype (Risk for Alzheimer Disease)
 
Specimen / Container (สิ่งส่งตรวจ/ภาชนะ):
Blood/ K3 EDTA (K3E) (Lavender Top) 3 mL, 1 tube or Buccal swab 1 tube

Document required:
1. Complete Consent form LAB-08170-Rev03-EN-Consent-for-Genomic-Medicine-Testing.pdf
2. Completed Requisition form LAB-REQ03-Rev01-0616.pdf
 
Turnaround Time (ระยะเวลารอผล):
Within 5 days
Tested Monday and Friday. Receive before 08:00 a.m. Report 18:00 p.m.
 
Useful For (ประโยชน์การทดสอบ):
Identifying patients who may be at risk for altered cholesterol metabolism and transportation. This event has associated with increase the risk for Alzheimer disease.
 
Methodology (วิธีการทดสอบ):
Real-time PCR
 
Test List In Profile (การทดสอบใน Profile):
APOE Alleles e2, e3 and e4
 
AliasesName (ชื่อเรียกอื่นๆ) :
Apolipoprotein E genotyping,
APOE
Alzheimer 
 
 
 
Test Code (รหัสการทดสอบ):
092-10-0025
Order Name (ชื่อการทดสอบ):
APOE Genotype (Risk for Alzheimer Disease)
 
Collection Specimen Or Container (สิ่งส่งตรวจ/ภาชนะ):
Blood/ K3 EDTA (K3E) (Lavender Top) 3 mL, 1 tube or Buccal swab 1 tube

Document required:
1. Complete Consent form LAB-08170-Rev03-EN-Consent-for-Genomic-Medicine-Testing.pdf
2. Completed Requisition form LAB-REQ03-Rev01-0616.pdf
 
Specimen Testing Type (สิ่งส่งตรวจที่ใช้ในการทดสอบ):
Whole blood, K3 EDTA (K3E) (Lavender Top) 3 mL, 1 tube, minimum volume 1.5 ml
or Buccal swab 1 tube
 
Sub Mission Container (ภาชนะส่งตรวจ):
K3 EDTA (K3E) (Lavender Top) or Buccal swab 1 tube
 
Rejection Criteria (เกณฑ์ปฏิเสธสิ่งส่งตรวจ):
Use heparin as anticoagulant.
Severe clotted specimen.
 
Specimen Stabillity (ความคงตัวของสิ่งส่งตรวจ):
Specimen Type Temperature Time
EDTA whole blood Refrigerated, 2oC to 8oC 7 days
 
 
 
Test Code (รหัสการทดสอบ):
092-10-0025
Order Name (ชื่อการทดสอบ):
APOE Genotype (Risk for Alzheimer Disease)
 
Method detail (วิธีการทดสอบ):
Real-time PCR
 
Schedule (ตารางการทดสอบ):
Monday and Friday 
 
Turnaround Time (ระยะเวลารอผล):
Within 5 days
Tested Monday and Friday. Receive before 08:00 a.m. Report 18:00 p.m.
 
Performing Location (หน่วยงานที่ทำการทดสอบ):
Clinical Genomics Tel. 14252
 
Specimen Retention Time (ระยะเวลาเก็บสิ่งส่งตรวจ):
3 months
 
 
 
Test Code (รหัสการทดสอบ):
092-10-0025
Order Name (ชื่อการทดสอบ):
APOE Genotype (Risk for Alzheimer Disease)
 
 
Clinical Information (ข้อมูลทางคลินิก):
Apolipoprotein E (ApoE) locates on 19q13.2 and consists of 299 amino in length. It plays an important role in cholesterol transportation and metabolism. Three most common alleles of ApoE are e3 (Cys112/Arg158), e2(Cys112/Cys158) and e4(Arg112/Arg158). Among these three alleles, e3 is the wildtype and most commonly found. Among these three alleles, ApoE3 is the wildtype and most commonly found. Mutation in ApoE might increase or decrease the risk for Alzheimer’s disease. Individuals with APOE e3/e4 genotype have a three-to-four-fold relative risk while individuals with APOE e4/e4 genotype have a 15-fold relative risk compared to those with the APOE e3/e3 genotype. Other than the risk at Late-onset Alzheimer developing, these mutations are related with the age of onset for the disease. The average age of developing Late-onset Alzheimer is 68 years at 94% for HomozygyousE4, 76 years at 47% frequency for hetrozygousE4 and 84 years at 20% frequency for those who do not carry E4.

Please find example report from this link below
5-APOE-genotype-(for-Alzheimer-s-disease)_pos_E4E4.pdf
 
Reference Value (ค่าอ้างอิง):
Wild-type of APOE gene (e3/e3)
 
Clinical Reference (เอกสารอ้างอิง):
  1. Goldman JS, Hahn SE, Catania JW, et al. Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med. 2011 Jun;13(6):597-605.
  2. Van Cauwenberghe C, Van Broeckhoven C, Sleegers K. The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med. 2016 May;18(5):421-30.
  3. Li Z, Shue F, Zhao N, et al. APOE2: protective mechanism and therapeutic implications for Alzheimer's disease. Mol Neurodegener. 2020 Nov 4;15(1):63.